British doctors lobby NHS to use cheap Avastin over Lucentis in AMD

Here's a new threat to Lucentis, the eye drug from Roche ($RHHBY) and Novartis ($NVS). British doctors are calling for the National Health Service to routinely use Roche's cancer med Avastin to treat patients with wet age-related macular degeneration, rather than the much costlier Lucentis. The two drugs work in a similar fashion and some studies show they work equally well for eye problems, but Avastin isn't licensed for use in the eye. Report

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.

Eli Lilly is joining Team USA as an official sponsor for the first time, backing Olympic and Paralympic athletes headed to Tokyo this summer.